Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
| Revenue (Most Recent Fiscal Year) | $119.91M |
| Net Income (Most Recent Fiscal Year) | $-56.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 154.00 |
| Pre-Tax Margin (Trailing 12 Months) | -2.31% |
| Net Margin (Trailing 12 Months) | -37.15% |
| Return on Equity (Trailing 12 Months) | -3.88% |
| Return on Assets (Trailing 12 Months) | -3.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.07 |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 14.18M |
| Free Float | 13.06M |
| Market Capitalization | $208.24M |
| Average Volume (Last 20 Days) | 0.09M |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.86% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |